Quadrature Capital Ltd Has $969,000 Stock Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Quadrature Capital Ltd raised its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 81.6% in the 1st quarter, Holdings Channel reports. The firm owned 27,354 shares of the life sciences company’s stock after acquiring an additional 12,290 shares during the period. Quadrature Capital Ltd’s holdings in Integra LifeSciences were worth $969,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IART. Signaturefd LLC boosted its stake in shares of Integra LifeSciences by 248.5% in the 4th quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock valued at $25,000 after purchasing an additional 415 shares in the last quarter. Hexagon Capital Partners LLC boosted its position in Integra LifeSciences by 123.3% in the fourth quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock valued at $29,000 after buying an additional 370 shares in the last quarter. Valley National Advisers Inc. acquired a new position in shares of Integra LifeSciences during the first quarter worth $63,000. Mitsubishi UFJ Asset Management UK Ltd. bought a new position in shares of Integra LifeSciences in the 4th quarter valued at $131,000. Finally, Northwest Investment Counselors LLC acquired a new stake in shares of Integra LifeSciences during the 1st quarter valued at $143,000. 84.78% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on IART shares. StockNews.com downgraded Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Monday, May 13th. Morgan Stanley boosted their target price on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a report on Monday, July 15th. Citigroup raised their price target on shares of Integra LifeSciences from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Wednesday, July 10th. JMP Securities lowered their target price on Integra LifeSciences from $49.00 to $40.00 and set a “market outperform” rating for the company in a research report on Tuesday, May 7th. Finally, Truist Financial increased their price target on Integra LifeSciences from $25.00 to $32.00 and gave the company a “hold” rating in a research note on Tuesday, July 16th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $32.86.

Integra LifeSciences Stock Performance

Shares of IART traded down $0.10 during mid-day trading on Friday, hitting $31.43. The stock had a trading volume of 1,562,854 shares, compared to its average volume of 1,327,015. The firm has a market cap of $2.48 billion, a P/E ratio of 62.86, a PEG ratio of 1.14 and a beta of 1.11. Integra LifeSciences Holdings Co. has a 52 week low of $22.36 and a 52 week high of $46.75. The company has a debt-to-equity ratio of 1.15, a current ratio of 4.68 and a quick ratio of 3.35. The business has a fifty day moving average price of $29.75 and a 200-day moving average price of $33.84.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Monday, May 6th. The life sciences company reported $0.55 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.55. Integra LifeSciences had a net margin of 2.63% and a return on equity of 14.27%. The business had revenue of $368.90 million during the quarter, compared to analyst estimates of $361.96 million. During the same period in the previous year, the business earned $0.74 EPS. Integra LifeSciences’s revenue was down 3.2% compared to the same quarter last year. On average, equities research analysts expect that Integra LifeSciences Holdings Co. will post 3.03 EPS for the current year.

Insider Buying and Selling

In related news, Chairman Stuart Essig bought 52,641 shares of Integra LifeSciences stock in a transaction on Thursday, May 23rd. The stock was acquired at an average price of $28.49 per share, with a total value of $1,499,742.09. Following the acquisition, the chairman now directly owns 487,922 shares of the company’s stock, valued at $13,900,897.78. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 3.10% of the stock is currently owned by insiders.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.